Celltrion Secures KRW 294.9B Manufacturing Deal, Boosting U.S. CDMO Operations

Celltrion has signed a major contract worth KRW 294.9 billion to produce biopharmaceutical ingredients for a global pharmaceutical company at its newly acquired U.S. plant.

This deal is driven by U.S. policies like the BIOSECURE Act and potential tariffs, which are pushing pharmaceutical companies to secure manufacturing partners within the United States.

The contract validates Celltrion's strategy to expand its contract development and manufacturing (CDMO) business and proves it can quickly secure clients for its new U.S. facility.

Celltrion recently announced a significant manufacturing contract worth KRW 294.9 billion, a major step in its global expansion.

This isn't just another business deal; it's the first major validation of Celltrion's bold strategy to acquire a U.S. manufacturing plant. Earlier this year, Celltrion completed the purchase of a facility in Branchburg, New Jersey, from Eli Lilly. By quickly signing a large contract with a new global client, Celltrion is proving it can successfully utilize this new asset and generate revenue, easing investor concerns about the large investment.

So, what’s driving this demand for U.S.-based manufacturing? The answer lies in a powerful combination of political and economic pressures that have reshaped the global pharmaceutical supply chain.

First, there's the BIOSECURE Act. Passed in late 2025, this U.S. law restricts government agencies from doing business with certain Chinese biotech companies. This has created a ripple effect, causing global pharmaceutical firms to shift their supply chains away from China and seek reliable partners in the U.S. and allied nations. It's a clear move to de-risk and diversify their manufacturing footprint.

Second, the threat of high tariffs has intensified the "Made in America" push. The U.S. administration announced plans for a 100% tariff on certain imported drugs unless companies commit to local production. This policy effectively makes U.S.-based manufacturing a strategic necessity for global drugmakers wanting to access the world's largest healthcare market.

Celltrion anticipated this shift perfectly. The acquisition of the Branchburg facility was a calculated move to position itself as a key solution for pharmaceutical companies navigating these new geopolitical realities. This new contract for drug substance (DS), the active ingredient in a medicine, shows that the strategy is already paying off. It also helps Celltrion compete more directly with rivals like Samsung Biologics, which has also seen massive growth by capitalizing on the demand for non-Chinese manufacturing partners.

In essence, this deal is a crucial milestone. It turns a strategic investment into tangible revenue and establishes Celltrion's new U.S. facility as a credible and active player in the global CDMO market.

CDMO (Contract Development and Manufacturing Organization): A company that provides comprehensive services from drug development through drug manufacturing on a contract basis for the pharmaceutical industry.
BIOSECURE Act: A U.S. law aimed at preventing foreign adversaries, particularly certain Chinese biotech companies, from accessing U.S. genetic data and markets, which has led to a re-sourcing of biomanufacturing.
Drug Substance (DS): The active ingredient in a pharmaceutical product that is responsible for its therapeutic effect. It is also known as the active pharmaceutical ingredient (API).